(Q42549226)

English

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

scientific article published on June 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

N J Yogelzang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J E Herndon

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

D C Harmon

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J M Corson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Y Suzuki

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M L Citron

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M R Green

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

0 references

publication date

1 June 1997

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

79

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

2237-2242

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Diffuse malignant mesothelioma. Prospective evaluation of 69 patients

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970601%2979%3A11%3C2237%3A%3AAID-CNCR23%3E3.0.CO%3B2-W

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179072%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42549226&oldid=1782305533"